Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Patients with acute coronary syndrome who used a genetic test to select an antiplatelet drug were 42% less likely to have a cardiovascular (CV) event or major bleeding, according to a study presented Sunday at the 67th Scientific Session of the American College of Cardiology, taking place in Orlando, Florida.
The journey to better women's heart health starts with having more data, said Nanette Kass Wenger, MD, MACC, MACP, FAHA, professor of cardiology at Emory University School of Medicine, during the Simon Dack Keynote Lecture, which opened the 67th Scientific Session of the American College of Cardiology.
Coverage of the 67th Scientific Session of the American College of Cardiology.
The study will be presented during the 67th American College of Cardiology Scientific Session in Orlando, Florida.
Arkansas became the third state to create work requirements for Medicaid since the Trump administration announced it would allow them.
A study being presented at the upcoming meeting of the American College of Cardiology found a dose–response relationship between walking and reduced heart failure risk.
Aledade and Horizon Blue Cross and Blue Shield of New Jersey partner to help practices take advantage of payment models that reward physicians who offer better quality care while lowering costs.
Coverage of updates in value from Patient-Centered Oncology Care, November 16-17, 2017.
Coverage of patient-centered care updates from Patient-Centered Oncology Care, November 16-17, 2017.
Coverage of patient-centered care from Patient-Centered Oncology Care, November 16-17, 2017.
Coverage of regulatory changes from Patient-Centered Oncology Care, November 16-17, 2017.
Coverage of regulatory changes from Patient-Centered Oncology Care, November 16-17, 2017.
Coverage of the Keynote Address from Patient-Centered Oncology Care, November 16-17, 2017.
In the next phase of the program, researchers will dig into the data they have gathered so far to identify the best practices for reducing 30- and 90-day readmission rates.
A symposium at Seton Hall Law School examined the role of care coordination and transitions in helping those with substance use disorder find success in treatment. Some experts say that managed care has not supported care coodination despite evidence that it works and ultimately saves money for health systems.
CAR T- cell therapies are among the most expensive ever invented. For now, there’s a lot of uncertainty, as both government and commercial insurers, and a handful of the nation’s leading cancer centers, navigate a reimbursement structure that truly has no precedent.
Ipililumumab's role in treating melanoma will change, as the immunotherapy will likely become part of different combinations than we see today.
Two stories--of taking part in clinical trials, and of serving as a voice for patients among scientists who run them--highlight how the advances in cancer are built on the trust between those living with the disease and the clinicians on the frontiers of care.
A survey of healthcare executives finds that ongoing issues with interoperability are holding back the transition to value-based reimbursement mechanisms. Humana's Chief Medical Officer, Roy A. Beveridge, MD, said the healthcare system must demand the same level of seamlessness seen in the banking industry.
Flatiron Health expects to maintain its current business model in the transaction.
The study used a claims database to examine records from patients who switched between long-acting insulins.
Such a large drop in Americans' sense of well-being in their daily lives in a time of economic good fortune is unprecedented, index organizers say.
Of the 262 patients with type 2 diabetes in the intervention, 83% stuck with it through the first year, despite significant requirements.
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Critics of the non-emergency transportation benefit cite the potential for fraud, but others say transportation often tops the list of reasons people miss medical appointments.
Despite an official policy since early 2017 that calls for Medicare to cover CGM for certain beneficiaries with diabetes, an attorney who won a landmark case prior to the policy change reports that beneficiaries are still being denied coverage.
Trump's calls for cracking down on drug prices and enacting right-to-try legislation bring a reaction on Wall Street, but speaking for less than a minute on on the opioid crisis brings a different response from Democratic lawmakers.
President Donald Trump returned to a popular campaign theme in Tuesday’s State of the Union address when he vowed to bring down the high cost of prescription drugs.
Empagliflozin (Jardiance) and another SGLT2 inhibitor, canagliflozin (Invokana) have been competing aggressively; both have clinical trial results showing cardiovascular benefits.
Officials at Omada Health said the PREDICTS trial was planned long before CMS decided not to include virtual providers in this spring's launch of the Medicare Diabetes Prevention Program. But a spokesperson said the company hopes the growing body of evidence in support of virtual programs will "assuage any concerns."